Erste Asset Management Gmb H Chinook Therapeutics, Inc. Transaction History

Erste Asset Management Gmb H

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 26, 2024	SELL	$0.0 - $40.39 $0 - $12.4 Million	-307,769 Closed	0 $0
Q4 2022 Nov 26, 2024	SELL	$18.63 - $27.35 $279,450 - $410,250	-15,000 Reduced 4.65%	307,769 $8.06 Billion
Q3 2022 Nov 26, 2024	BUY	$17.51 - $23.37 $5.39 Million - $7.19 Million	307,769 New	307,769 $6.05 Billion
Q2 2022 Nov 26, 2024	BUY	$12.59 - $18.8 $4.06 Million - $6.07 Million	322,769 New	322,769 $5.65 Billion
Q1 2022 Nov 22, 2024	BUY	$12.02 - $16.69 $1.02 Million - $1.42 Million	85,000 Added 32.53%	346,269 $5.66 Billion
Q4 2021 Nov 22, 2024	BUY	$10.69 - $16.83 $3.27 Million - $5.15 Million	306,269 New	306,269 $4.94 Billion
Q3 2021 Nov 22, 2024	BUY	$11.5 - $14.86 $345,000 - $445,800	30,000 Added 12.97%	261,269 $3.33 Billion
Q2 2021 Nov 22, 2024	BUY	$13.6 - $18.98 $340,000 - $474,500	25,000 Added 12.12%	231,269 $3.27 Billion
Q1 2021 Nov 22, 2024	BUY	$14.17 - $19.11 $221,052 - $298,116	15,600 Added 8.18%	206,269 $3.21 Billion
Q4 2020 Nov 22, 2024	BUY	$11.9 - $20.91 $2.27 Million - $3.99 Million	190,669 New	190,669 $3.1 Billion

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.